Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: Molecular mechanisms and effects on matrix interactions

Journal of Lipid Research

Volumn 41, Issue 11, 2000, Pages 1703-1714

  Oorni, K ^a   Pentikainen, M O ^a   Ala Korpela, M ^a   Kovanen, P T ^a  

^a WIHURI RESEARCH INSTITUTE   (Finland)

Author keywords

Cholesterol esterase; Lipoprotein lipase; Oxidation; Phospholipase A2; Phospholipase C; Proteoglycans; Proteolysis; Sphingomyelinase

Indexed keywords

CHOLESTEROL ESTERASE; FAT DROPLET; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE C; PROTEOGLYCAN; SPHINGOMYELIN PHOSPHODIESTERASE;

ARTERY INTIMA; ATHEROSCLEROSIS; BINDING AFFINITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; HYDROLYSIS; IN VITRO STUDY; LIPID OXIDATION; LIPID STORAGE; LIPID VESICLE; LIPOLYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMALS; ARTERIES; ARTERIOSCLEROSIS; CHEMISTRY, PHYSICAL; ENDOPEPTIDASES; EXTRACELLULAR MATRIX; HUMANS; LIPOLYSIS; LIPOPROTEINS, LDL; LIPOSOMES; PROTEOGLYCANS;

EID: 0033729477     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. The vascular extracellular matrix
2. Mapping of proteoglycans in atherosclerotic lesions
3. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-β
4. Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis
5. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis
6. An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit
7. The proteoglycan decorin links low density lipoproteins with collagen type I
8. Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding
9. Engineering non-atherogenic low density lipoproteins: Direct evidence for the 'response-toretention' hypothesis of atherosclerosis
10. The response-to-retention hypothesis of early atherogenesis
11. The response-to-retention hypothesis of atherogenesis reinforced
12. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions
13. Lipoprotein lipase is synthesized by macrophage-derived foam cells in human coronary atherosclerotic plaques
14. Expression of lipoprotein lipase mRNA and secretion in macrophages isolated from human atherosclerotic aorta
15. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in vivo
16. Intimal thickenings of human aorta contain modified reassembled lipoproteins
17. Electron microscopy of lipid deposits in human atherosclerosis
18. Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta
19. Cholesterol esterification in macrophages. Stimulation by lipoproteins containing apo B isolated from human aortas
20. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man
21. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation
22. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima
23. Immunological properties of apoB-containing lipoprotein particles in human atherosclerotic arteries
24. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque
25. Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation
26. Malondialdehydealtered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits
27. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima
28. Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques
29. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima
30. In vivo action of 15-lipoxygenase in early stages of human atherogenesis
31. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques
32. Low density lipoprotein undergoes oxidative modification in vivo
33. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides
34. Presence of hypochlorite-modified proteins in human atherosclerotic lesions
35. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry
36. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complex in the early atherosclerotic lesion
37. The relationship between plasma and tissue lipids in human atherosclerosis
38. Extracellular lipid deposition in atherosclerosis
39. Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue
40. Characterization of two unique cholesterol-rich lipid particles isolated from human atherosclerotic lesions
41. Cholesterol deposition in atherosclerotic lesions
42. Evidence for loss of apo B from LDL, in human atherosclerotic lesions: Extracellular cholesteryl ester lipid particles lacking apo B
43. Characterization of two lipoproteins containing apolipoproteins B and E from lesion-free human aortic intima
44. Apo-lipoprotein localization in human atherosclerotic arteries
45. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages
46. Elimination of macrophage-specific apolipoprotein E reduces diet-induced atherosclerosis in C57BL/6J male mice
47. Unesterified cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas
48. Prelesional events in atherogenesis. Colocalization of apolipoprotein B, unesterified cholesterol and extracellular phospholipid liposomes in the aorta of hyperlipidemic rabbit
49. Early extracellular and cellular lipid deposits in aorta of cholesterol-fed rabbits
50. Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins
51. Purification and partial characterization of extracellular liposomes isolated from the hyperlipidemic rabbit aorta
52. Ca++ antagonists and ACAT inhibitors promote cholesterol efflux from macrophages by different mechanisms. II. Characterization of intracellular morphologic changes
53. Mast cells of two types differing in neutral protease composition in the human aortic intima. Demonstration of tryptase- and tryptase/chymase-containing mast cells in normal intimas, fatty streaks, and the shoulder regions of atheromas
54. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
55. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice
56. Plasma kallikrein localisation in human blood vessels
57. Kallikrein release by vascular tissue
58. Prothrombin-related antigens in human aortic intima
59. Lysosomal proteases in the normal and atherosclerotic arterial wall
60. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells
61. Low density lipoprotein degradation by secretory granules of rat mast cells. Sequential degradation of apolipoprotein B by granule chymase and carboxypeptidase A
62. Proteolytic enzymes of mast cell granules degrade low density lipoproteins and promote their granule-mediated uptake by macrophages in vitro
63. Macrophage proteases can modify low density lipoproteins to increase their uptake by macrophages
64. Fusion of proteolyzed low-density lipoprotein in the fluid phase: A novel mechanism generating atherogenic lipoprotein particles
65. 2 in human atherosclerotic plaques
66. 2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins
67. 2 in atherosclerotic and nonatherosclerotic regions of human arteries
68. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling
69. Sphingomyelinase, an enzyme implicated in atherogenesis, is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular matrix
70. 2 type II to proteoglycans. Differential effect of glycosaminoglycans on enzyme activity
71. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development
72. Pancreatic carboxyl ester lipase: A circulating enzyme that modifies normal and oxidized lipoproteins in vitro
73. Synthesis and secretion of the pancreatic-type carboxyl ester lipase by human endothelial cells
74. Role of acid lipase in cholesteryl ester accumulation during atherogenesis. Correlation of enzyme activity with acid lipase-containing macrophages in rabbit and human lesions
75. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions
76. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions
77. Expression of heme oxygenase-1 in athcrosclerotic lesions
78. Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions - Colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins
79. Expression of NADH/NADPH oxidase p22phox in human coronary arteries
80. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material
81. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions
82. Metal ion release from mechanically-disrupted human arterial wall. Implications for the development of atherosclerosis
83. Transition metal ions within human atherosclerotic lesions can catalyse the oxidation of low density lipoprotein by macrophages
84. The role of lipid peroxidation and antioxidants in oxidative modification of LDL
85. Packing of cholesterol molecules in human low-density lipoprotein
86. Organization of phosphatidylcholine and sphingomyelin in the surface monolayer of low density lipoprotein and lipoprotein(a) as determined by time-resolved fluorometry
87. Evidence for distinct behaviour of phosphatidylcholine and sphingomyelin at the low density lipoprotein surface
88. Influence of molecular packing and phospholipid type on rates of cholesterol exchange
89. Does cholesterol discriminate between sphingomyelin and phosphatidylcholine in mixed monolayers containing both phospholipids?
90. Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering
91. Fluorescence study of the motional states of core and surface lipids in native and reconstituted low density lipoproteins
92. Hydrolysis of cholesteryl ester in low density lipoprotein converts this lipoprotein into a liposome
93. On the pathogenesis of atherosclerosis: Enzymatic transformation of human low density lipoprotein to an atherogenic moiety
94. Proteolysis and fusion of low density lipoprotein particles independently strengthen their binding to exocytosed mast cell granules
95. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages
96. Aggregation and fusion of modified low density lipoprotein
97. 2 only aggregation, of low density lipoprotein particles. Two distinct mechanisms leading to increased binding strength of LDL to human aortic proteoglycans
98. 2
99. Sphingomyelinase induces lipid microdomain formation in a fluid phosphatidylcholine/sphingomyelin membrane
100. 31p NMR study
101. 2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells
102. Alterations in the physicochemical characteristics of low and high density lipoproteins after lipolysis with phospholipase A2. A spin-label study
103. Enzymatic probes of lipoprotein structure. Hydrolysis of human serum low density lipoprotein-2 by phospholipase A2
104. Phospholipase A(2) modification of low density lipoprotein forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans
105. Differential effects of glycero- and sphingo-phospholipolysis on human high-density lipoprotein fluidity
106. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin
107. Modifications of low-density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate
108. The structural stability of low-density lipoprotein. A kinetic X-ray scattering study of its interaction with arterial proteoglycans
109. 13C NMR
110. Phagocytosis of aggregated lipoprotein by macrophages: Low density lipoprotein receptor-dependent foam-cell formation
111. Prevention of phospholipase-C induced aggregation of low density lipoprotein by amphipathic apolipoproteins
112. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I
113. Conversion of human low density lipoprotein into a very low density lipoprotein-like particle in vitro
114. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition
115. Characterization of aggregated low density lipoproteins induced by copper-catalyzed oxidation
116. Structural and functional properties of apolipoprotein B in chemically modified low density lipoproteins
117. In vitro formation of oxidatively-modified and reassembled human low-density lipoproteins: Antioxidant effect of albumin
118. Oxidation-induced aggregation of rabbit low-density lipoprotein by azo initiator
119. Time-course studies by synchrotron X-ray solution scattering of the structure of human low-density lipoprotein during Cu(2+)-induced oxidation in relation to changes in lipid composition
120. Free radical modification of lipoproteins and cholesterol accumulation in cells upon atherosclerosis
121. Microsomal lipid peroxidation causes an increase in the order of the membrane lipid domain
122. NMR analysis of low-density lipoprotein oxidatively-modified in vitro
123. Spin-labeling study of the oxidative damage to low-density lipoprotein
124. The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans
125. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: Its possible role in atherogenesis
126. Human apolipoprotein B-100 heparin-binding sites
127. Identification of apoB-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans
128. Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes
129. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans
130. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans
131. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/E receptor
132. Well-defined regions of apolipoprotein B-100 undergo conformational change during its intravascular metabolism
133. Inflammatory and atherogenic lipoprotein markers in patients with rheumatoid arthritis
134. The affinity of low density lipoproteins for an arterial macromolecular complex: A study in ischemic heart disease and controls
135. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction
136. Proteolysis and fusion of low density lipoprotein particles strengthen their binding to human aortic proteoglycans
137. 13C NMR characterization of lysine residues in apolipoprotein B and their role in binding to the low density lipoprotein receptor
138. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products
139. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins
140. Oxidation of low density lipoprotein particles decreases their ability to bind to human aortic proteoglycans. Dependence on oxidative modification of the lysine residues
141. Hypochlorite oxidizes lysine residues of heparin-bound LDL, and releases LDL from immobilized heparin
142. Lipoprotein lipase and lipolysis: Central roles in lipoprotein metabolism and atherogenesis
143. Oxidation of low density, lipoproteins greatly enhances their association with lipoprotein lipase anchored to the endothelial matrix
144. Lipoprotein lipase (LPL) strongly links native anti oxidized low density lipoprotein particles to decorin-coated collagen. Roles for both dimeric and monomeric forms of LPL
145. Human arterial proteoglycans increase the rate of proteolytic fusion of low density lipoprotein particles
146. Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells
147. Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions
148. Mast cells in human fatty streaks and atheromas: Implications for intimal lipid accumulation